• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组NcSRS2在不同免疫刺激复合物(ISCOM)制剂中对小鼠脑新孢子虫病的免疫原性和保护作用

Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations.

作者信息

Pinitkiatisakul Sunan, Friedman Mikaela, Wikman Maria, Mattsson Jens G, Lövgren-Bengtsson Karin, Ståhl Stefan, Lundén Anna

机构信息

Department of Parasitology (SWEPAR), National Veterinary Institute and Swedish University of Agricultural Sciences, SE-751 89 Uppsala, Sweden.

出版信息

Vaccine. 2007 May 4;25(18):3658-68. doi: 10.1016/j.vaccine.2007.01.074. Epub 2007 Jan 24.

DOI:10.1016/j.vaccine.2007.01.074
PMID:17280751
Abstract

Recombinant NcSRS2, a major immunodominant surface antigen of the intracellular protozoan parasite Neospora caninum, was used as a model antigen to compare the immunogenicity of iscoms prepared according to three different methods. Two NcSRS2 fusion proteins were used, one that was biotinylated upon expression in Escherichia coli and linked to Ni2+-loaded iscom matrix (iscom without any protein) via a hexahistidyl (His6)-tagged streptavidin fusion protein, and another that contained both a His6-tag and streptavidin (His6-SA-SRS2') and was coupled to either Ni2+-loaded or biotinylated matrix. While all three iscom preparations induced N. caninum specific antibodies at similar levels, His6-SA-SRS2' coupled to biotinylated matrix generated the strongest cellular responses measured as in vitro proliferation and production of interferon-gamma and interleukin-4 after antigen stimulation of spleen cells. However, the relationship between the levels of these cytokines as well as between IgG1 and IgG2a titres in serum induced by the three iscom preparations were similar, indicating that the balance between Th1 and Th2 responses did not differ. After challenge infection, mice immunised with His6-SA-SRS2' coupled to biotinylated matrix had significantly lower amounts of parasite DNA in their brains compared to the other immunised groups. Possible reasons for the performance of the different iscom formulations are discussed.

摘要

重组NcSRS2是细胞内原生动物寄生虫犬新孢子虫的一种主要免疫显性表面抗原,被用作模型抗原来比较根据三种不同方法制备的免疫刺激复合物(iscom)的免疫原性。使用了两种NcSRS2融合蛋白,一种在大肠杆菌中表达时被生物素化,并通过六聚组氨酸(His6)标记的链霉亲和素融合蛋白与负载Ni2+的iscom基质(不含任何蛋白质的iscom)相连,另一种同时含有His6标签和链霉亲和素(His6-SA-SRS2'),并与负载Ni2+或生物素化的基质偶联。虽然所有三种iscom制剂诱导犬新孢子虫特异性抗体的水平相似,但与生物素化基质偶联的His6-SA-SRS2'在脾细胞抗原刺激后,以体外增殖以及干扰素-γ和白细胞介素-4的产生来衡量,产生了最强的细胞反应。然而,三种iscom制剂诱导的血清中这些细胞因子水平之间以及IgG1和IgG2a滴度之间的关系相似,表明Th1和Th2反应之间的平衡没有差异。攻毒感染后,与其他免疫组相比,用与生物素化基质偶联的His6-SA-SRS2'免疫的小鼠大脑中的寄生虫DNA量显著降低。讨论了不同iscom制剂表现的可能原因。

相似文献

1
Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations.重组NcSRS2在不同免疫刺激复合物(ISCOM)制剂中对小鼠脑新孢子虫病的免疫原性和保护作用
Vaccine. 2007 May 4;25(18):3658-68. doi: 10.1016/j.vaccine.2007.01.074. Epub 2007 Jan 24.
2
Reduced cerebral infection of Neospora caninum in BALB/c mice vaccinated with recombinant Brucella abortus RB51 strains expressing N. caninum SRS2 and GRA7 proteins.用表达犬新孢子虫SRS2和GRA7蛋白的重组流产布鲁氏菌RB51菌株接种的BALB/c小鼠,其大脑中犬新孢子虫感染减少。
Vet Parasitol. 2007 Sep 30;148(3-4):219-30. doi: 10.1016/j.vetpar.2007.06.029. Epub 2007 Jul 24.
3
Immunisation of mice against neosporosis with recombinant NcSRS2 iscoms.用重组NcSRS2免疫刺激复合物对小鼠进行新孢子虫病免疫接种。
Vet Parasitol. 2005 Apr 20;129(1-2):25-34. doi: 10.1016/j.vetpar.2004.12.004.
4
Applying biotin-streptavidin binding for iscom (immunostimulating complex) association of recombinant immunogens.将生物素-链霉亲和素结合应用于重组免疫原与免疫刺激复合物(iscom)的结合。
Biotechnol Appl Biochem. 2005 Apr;41(Pt 2):163-74. doi: 10.1042/BA20040060.
5
Immunization with native surface protein NcSRS2 induces a Th2 immune response and reduces congenital Neospora caninum transmission in mice.用天然表面蛋白NcSRS2进行免疫可诱导Th2免疫反应,并减少小鼠先天性犬新孢子虫的传播。
Int J Parasitol. 2005 Nov;35(13):1407-15. doi: 10.1016/j.ijpara.2005.05.013. Epub 2005 Jul 18.
6
Vaccination with microneme protein NcMIC4 increases mortality in mice inoculated with Neospora caninum.用微线体蛋白NcMIC4进行疫苗接种会增加接种犬新孢子虫的小鼠的死亡率。
J Parasitol. 2007 Oct;93(5):1046-55. doi: 10.1645/GE-1181R1.1.
7
Quantitative analysis of parasite DNA in the blood of immunized and naïve mice after infection with Neospora caninum.感染犬新孢子虫后,对免疫小鼠和未免疫小鼠血液中寄生虫DNA进行定量分析。
Parasitology. 2008 Feb;135(2):175-82. doi: 10.1017/S0031182007003733. Epub 2007 Oct 9.
8
Immunogenicity of a DNA vaccine expressing the Neospora caninum surface protein NcSRS2 in mice.表达犬新孢子虫表面蛋白NcSRS2的DNA疫苗在小鼠中的免疫原性。
Acta Vet Hung. 2009 Mar;57(1):51-62. doi: 10.1556/AVet.57.2009.1.5.
9
Reduced cerebral infection of Neospora caninum-infected mice after vaccination with recombinant microneme protein NcMIC3 and ribi adjuvant.用重组微线体蛋白NcMIC3和Ribi佐剂接种后,新孢子虫感染小鼠的脑部感染减少。
J Parasitol. 2003 Feb;89(1):44-50. doi: 10.1645/0022-3395(2003)089[0044:RCIONC]2.0.CO;2.
10
Low efficacy of NcGRA7, NcSAG4, NcBSR4 and NcSRS9 formulated in poly-ε-caprolactone against Neospora caninum infection in mice.聚己内酯制剂中 NcGRA7、NcSAG4、NcBSR4 和 NcSRS9 对小鼠新孢子虫感染的低疗效。
Vaccine. 2012 Jul 13;30(33):4983-92. doi: 10.1016/j.vaccine.2012.05.033. Epub 2012 May 26.

引用本文的文献

1
Neospora caninum SRS2 Protein: Essential Vaccination Targets and Biochemical Features for Next-Generation Vaccine Design.犬新孢子虫SRS2蛋白:下一代疫苗设计的关键疫苗靶点及生化特性
Biomed Res Int. 2022 Apr 6;2022:7070144. doi: 10.1155/2022/7070144. eCollection 2022.
2
Vaccines against a Major Cause of Abortion in Cattle, Neospora caninum Infection.牛新孢子虫感染——一种导致牛流产的主要原因的疫苗。
Animals (Basel). 2011 Sep 8;1(3):306-25. doi: 10.3390/ani1030306.
3
Immunization with oligomannose-coated liposome-entrapped dense granule protein 7 protects dams and offspring from Neospora caninum infection in mice.
用低聚甘露糖包被的脂质体包裹致密颗粒蛋白7进行免疫可保护母鼠及其后代免受小鼠新孢子虫感染。
Clin Vaccine Immunol. 2009 Jun;16(6):792-7. doi: 10.1128/CVI.00032-09. Epub 2009 Apr 8.